2023 European Society of Cardiology guidelines for the management of acute coronary syndromes : Statement of endorsement by the NVVC
- PMID: 39254829
- PMCID: PMC11413259
- DOI: 10.1007/s12471-024-01896-2
2023 European Society of Cardiology guidelines for the management of acute coronary syndromes : Statement of endorsement by the NVVC
Abstract
This review discusses the new recommendations in the 2023 European Society of Cardiology guidelines on the management of acute coronary syndrome and provides a perspective on topics specific to clinical practice in the Netherlands, including pre-treatment, antiplatelet agent strategies, the use of risk scores and logistical considerations with regard to the timing of coronary angiography.
Keywords: Acute coronary syndrome; Antiplatelet therapy; Guidelines; Percutaneous coronary intervention.
© 2024. The Author(s).
Conflict of interest statement
B. Zwart has received speakers/consultancy fees from Bayer and AstraZeneca. B.E.P.M. Claessen has received honoraria from Abbott Vascular, Abiomed, Amgen, B. Braun, Boston Scientific, Philips and Sanofi for consultancy, speaking engagements and/or advisory board engagements. P. Damman has received research grants from Abbott, Philips, AstraZeneca and consultancy fees from Philips. P. Woudstra has received speakers fees from Philips and consultancy fees from Sanofi. Y. Appelman has received research grants from the Dutch Heart Foundation. In the past 36 months, A.W.J. van ’t Hof has received unrestricted grants from Abbott Vascular, Boehringer Ingelheim, Sanofi and consultancy fees from Celecor Therapeutics. J.M. ten Berg has received institutional research grants ZonMw, Daiichi Sankyo and advisor fees from CeleCor. M.A. Vink, J.W. Balder, M.G. Dickinson, E.A. Badings, and F. Arslan declare that they have no competing interests.
Figures

Similar articles
-
2023 European Society of Cardiology guidelines on the management of cardiomyopathies : Statement of endorsement by the NVVC.Neth Heart J. 2025 May;33(5):148-156. doi: 10.1007/s12471-025-01955-2. Epub 2025 Apr 14. Neth Heart J. 2025. PMID: 40227490 Free PMC article.
-
Summary of the European Society of Cardiology guidelines on dual antiplatelet therapy in patients after percutaneous coronary interventions.Kardiol Pol. 2022;80(10):974-989. doi: 10.33963/KP.a2022.0198. Epub 2022 Aug 29. Kardiol Pol. 2022. PMID: 36036339 Review.
-
The Evolving Field of Acute Coronary Syndrome Management: A Critical Appraisal of the 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndrome.J Clin Med. 2024 Mar 25;13(7):1885. doi: 10.3390/jcm13071885. J Clin Med. 2024. PMID: 38610650 Free PMC article. Review.
-
Management of non-ST-segment elevation acute coronary syndrome: comparison of the updated guidelines from North America and Europe.Crit Pathw Cardiol. 2012 Jun;11(2):62-73. doi: 10.1097/HPC.0b013e3182563a7e. Crit Pathw Cardiol. 2012. PMID: 22595816 Review.
-
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy.Can J Cardiol. 2018 Mar;34(3):214-233. doi: 10.1016/j.cjca.2017.12.012. Epub 2017 Dec 19. Can J Cardiol. 2018. PMID: 29475527 Review.
Cited by
-
Timelines, targets, and transitions in cardiovascular care.Neth Heart J. 2025 Sep;33(9):249. doi: 10.1007/s12471-025-01984-x. Epub 2025 Aug 4. Neth Heart J. 2025. PMID: 40760386 Free PMC article. No abstract available.
-
Strengthening NVVC endorsements for ESC guidelines.Neth Heart J. 2024 Oct;32(10):337. doi: 10.1007/s12471-024-01905-4. Epub 2024 Sep 19. Neth Heart J. 2024. PMID: 39297917 Free PMC article. No abstract available.
-
A Moroccan Experience in the Management of Acute Coronary Syndrome Without ST-Segment Elevation: Clinical Profiles and Therapeutic Approaches.Cureus. 2025 Mar 6;17(3):e80155. doi: 10.7759/cureus.80155. eCollection 2025 Mar. Cureus. 2025. PMID: 40190966 Free PMC article.
-
Timing of invasive strategy in patients with non-ST segment elevation acute myocardial infarction: A nationwide retrospective cohort analysis.Neth Heart J. 2025 Sep;33(9):264-269. doi: 10.1007/s12471-025-01970-3. Epub 2025 Aug 4. Neth Heart J. 2025. PMID: 40760385 Free PMC article.
References
-
- Byrne RA, Rossello X, Coughlan JJ, et al. ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;2023:3720–826. - PubMed
-
- Montalescot G, van ’t Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371:1016–27. - PubMed
-
- Gewehr DM, et al. Pretreatment with P2Y12 inhibitors in ST-elevation myocardial infarction. Catheter Cardiovasc Interv. 2023;102:200–11. - PubMed
-
- Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS‑6 randomized trial. JAMA. 2006;295:1519–30. - PubMed
-
- Schüpke S, Neumann F‑J, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381:1524–34. - PubMed
Publication types
LinkOut - more resources
Full Text Sources